PARP1 and pancreatic neoplasm: Clinically, PARP inhibitors (PARPi), such as olaparib, niraparib, rucaparib, and talazoparib, exploit synthetic lethality in homologous recombination–deficient tumors and are increasingly applied in ovarian, breast, prostate, and pancreatic cancers.